Tonsillectomy,
does it really help with Reduction of sore-throat days in adults with recurrent acute tonsillitis?
research showsTonsillectomy is rated B because it reduced 24-month sore-throat days from 30 to 23, IRR 0.53 (95% CI 0.43 to 0.65). NATTINA allocated 455 participants, excluded two as ineligible to form an eligible intention-to-treat population of 453, and used 429 participants (224/205) in the actual primary model. It was open-label with a self-reported primary endpoint, and surgery-related adverse events occurred in 39%, including bleeding in 19%.
ads claimMarketing may imply that removing the tonsils prevents every sore throat. The evidence concerns reduction of symptom burden in adults meeting strict recurrent-tonsillitis criteria, not prevention of every viral upper respiratory infection.
Useful facts when choosing a product
- Tonsillectomy is surgery under general anesthesia, not a supplement or medicine.
- NATTINA enrolled adults meeting United Kingdom referral criteria for recurrent acute tonsillitis.
- Cumulative sore-throat days fell over 24 months even when postoperative throat pain was counted.
- Bleeding, infection, and anesthesia complications must be weighed against the benefit.
What the research actually shows
At 27 United Kingdom hospitals, NATTINA allocated 455 adults, then excluded two as ineligible to form an eligible intention-to-treat population of 453: 233 assigned to immediate surgery and 220 to conservative care. The actual primary model included 429 participants with at least one weekly sore-throat return, 224 and 205 respectively. The prespecified self-reported 24-month endpoint succeeded at 23 versus 30 sore-throat days, IRR 0.53 (95% CI 0.43 to 0.65). Surgery-related adverse events occurred in 39%, including bleeding in 19%. NATTINA was publicly funded by NIHR.
Why this is classified as B (68)
The direct symptom endpoint succeeded in an actual primary model of 429 after 455 were allocated and 453 formed the eligible intention-to-treat set, but open-label self-report and substantial surgical harms give B with 68 points.
Counterpoint. Adults with fewer recurrences or uncertain diagnosis may have a smaller absolute benefit.
Rejudgment record. Cross-check applied — Accepted success of the direct 24-month symptom endpoint but downgraded for an open-label trial with a self-reported primary endpoint and substantial harm: 39% surgery-related adverse events and 19% bleeding
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduction of cumulative sore-throat days over 24 months | B | The prespecified direct symptom primary endpoint succeeded in NATTINA. |
| Improved disease-specific quality of life in recurrent tonsillitis | B | NATTINA's TOI-14 results were directionally consistent with fewer sore-throat days. |
| Reduction of short-term sore-throat episodes | C | Two earlier adult trials were directionally positive but small, with 156 participants and short follow-up. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Wilson JA et al. 2023 (NATTINA) | Multicenter open-label randomized controlled trial | 205 | Public funding from the United Kingdom National Institute for Health and Care Research Health Technology Assessment programme | Sore-throat days recorded weekly for 24 months after randomization | Primary endpoint succeeded: 23 versus 30 sore-throat days over 24 months, IRR 0.53 (95% CI 0.43 to 0.65); surgery-related adverse events 39% and bleeding 19%. | Key direct symptom evidence |
| Burton MJ et al. 2014 Cochrane review | Systematic review of randomized trials | 156 | Academic Cochrane Ear, Nose and Throat Disorders Group review; not manufacturer-led | Sore-throat episodes and days over about six months | Surgery was associated with about 10.6 fewer sore-throat days, but samples were small and evidence quality was low. | Independent directional support |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Tonsillectomy x fewer sore-throat days in adult recurrent tonsillitis — Evidence Grade B·68. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/tonsillectomy-adult-recurrent-tonsillitis-sore-throat-days/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.